Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Uniqure NV
QURECurrent price
14.77 USD
+1.04 USD (+7.57%)
Last closed
13.70 USD
Company
www.uniqure.com
ISIN
NL0010696654
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
848 129 920 USD
Yield for 12 month
+176.07 %
1Y
3Y
5Y
10Y
15Y
QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Address: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
31.50 USDP/E ratio
–Dividend Yield
–Current Year
+15 843 000 USD
Last Year
+106 483 000 USD
Current Quarter
+2 287 000 USD
Last Quarter
+11 126 000 USD
Current Year
+2 215 000 USD
Last Year
+103 140 000 USD
Current Quarter
+1 266 000 USD
Last Quarter
+995 000 USD
Key Figures QURE
1 year
3 years
5 years
10 years
EBITDA
-189 319 008 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-16.62 %
PEG Ratio
–
Return On Equity TTM
-147.57 %
Wall Street Target Price
31.50 USD
Revenue TTM
28 587 000 USD
Book Value
1.15 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
62.50 %
Dividend Yield
–
Gross Profit TTM
-87 370 000 USD
Earnings per share
-4.95 USD
Diluted Eps TTM
-4.95 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
-18.20 %
Profit Margin
–
Dividend Analytics QURE
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History QURE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:5
Payout Ratio
–
Last Split Date
31.01.2014
Stock Valuation QURE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
27.93
Enterprise Value Revenue
13.40
Price Sales TTM
29.67
Enterprise Value EBITDA
0.99
Price Book MRQ
13.45
Financials QURE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators QURE
For 52 weeks
3.73 USD
17.71 USD
50 Day MA
7.04 USD
Shares Short Prior Month
3 167 279
200 Day MA
5.96 USD
Short Ratio
4.38
Shares Short
3 251 056
Short Percent
6.74 %
BeatStart